The impact of early molecular response in children and adolescents with chronic myeloid leukemia treated with imatinib: a single-center study from China.

Abstract:

:Chronic myeloid leukemia (CML) is rare among children and adolescents. The early molecular response (EMR) is an important prognostic significance for adult CML patients. This study explored the impact of EMR on the prognosis in 40 children and adolescents with CML-CP treated with imatinib (IM). Our results showed that a high proportion of patients failed to achieve the BCR-ABL1/ABL1 International Scale (IS) ≤ 10% at 3 months. Children with a BCR-ABL1/ABL1 ≤ 10% at 3 months and <1% at 6 months increased the rate of achieving complete cytogenetic response (CCyR) and/or major molecular response (MMR) at 12 months compared to those with BCR-ABL1/ABL1 > 10%. With a median follow-up of 42 months, patients with BCR-ABL1/ABL1 ≤ 10% showed a better 4-year event-free survival (EFS). In summary, achieving BCR-ABL1/ABL1 IS ≤10% at 3 months and <1% at 6 months would increase the possibility of achieving MMR, CCyR at 12 months and had a better 4-year EFS. EMR is a reliable prognosticator for young CML patients treated with IM.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Shao H,Zeng Z,Cen J,Zhang J,Bai S,Wu C,Gong Y,Wang Y,Qiu H,Chen S,Pan J

doi

10.1080/10428194.2017.1422860

subject

Has Abstract

pub_date

2018-09-01 00:00:00

pages

2152-2158

issue

9

eissn

1042-8194

issn

1029-2403

journal_volume

59

pub_type

杂志文章
  • Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia.

    abstract::A better understanding of events triggering chronic myeloid leukemia progression is critical for optimized clinical management of chronic myeloid leukemia (CML). We sought to validate that increased expression of Musashi 2 (MSI2), a post-transcription regulator, is associated with progression and prognosis. Screening ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.981175

    authors: Kaeda J,Ringel F,Oberender C,Mills K,Quintarelli C,Pane F,Koschmieder S,Slany R,Schwarzer R,Saglio G,Hemmati P,van Lessen A,Amini L,Gresse M,Vagge E,Burmeister T,Serra A,Carson A,Schwarz M,Westermann J,Jundt F,D

    更新日期:2015-07-01 00:00:00

  • Jejunal perforation in a patient with adult T-cell leukemia.

    abstract::We present a case of adult T-cell leukemia (ATL) with jejunal perforation at the site of intestinal involvement by ATL. A 39-year-old woman presented with sudden-onset abdominal pain. Physical examination showed generalized severe abdominal tenderness and intraabdominal free air was seen on radiographic examination. U...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109097774

    authors: Isomoto H,Ohnita K,Haraguchi M,Mizuta Y,Momita S,Ikeda S,Omagari K,Murase K,Nakayama T,Maeda T,Murata I,Kohno S

    更新日期:2001-11-01 00:00:00

  • Hypoxia inducible factor-1α induces chemoresistance phenotype in non-Hodgkin lymphoma cell line via up-regulation of Bcl-xL.

    abstract::Non-Hodgkin lymphoma (NHL) is one of the most common cancers in childhood. The development of chemoresistance in tumor cells is one of the principal causes of treatment failure. This resistance has been associated with different mechanisms, one being the overexpression of anti-apoptotic proteins such as Bcl-xL. It has...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.733874

    authors: Hernandez-Luna MA,Rocha-Zavaleta L,Vega MI,Huerta-Yepez S

    更新日期:2013-05-01 00:00:00

  • Acute promyelocytic leukemia in a HIV seropositive patient.

    abstract::Acute myeloid leukemia (AML) is infrequent in patients with human immunodeficiency virus (HIV) infection. Among AML, acute promyelocytic leukemia (APL) has been rarely described in such patients, with only one case being published. We report a 30 years-old intravenous drug abuser HIV-infected male with APL who attaine...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199709050899

    authors: Calvo R,Ribera JM,Battle M,Sancho JM,Granada I,Flores A,Millá F,Feliu E

    更新日期:1997-08-01 00:00:00

  • Fas receptor (CD95)-mediated apoptosis in leukemic cells.

    abstract::Binding of Fas ligand (FasL) or an agonistic anti-Fas receptor (Fas/CD95) antibody induces apoptosis in Fas-bearing target cells. The involvement of Fas/FasL pathway has been investigated in human acute myelogenous leukemia (AML) cells. Fas/CD95 is expressed on a majority of AML cells, although the intensity of expres...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199709042492

    authors: Komada Y,Sakurai M

    更新日期:1997-03-01 00:00:00

  • Novel tumor markers provide improved prediction of survival after diagnosis of human immunodeficiency virus (HIV)-related diffuse large B-cell lymphoma.

    abstract::Existing prognostic tools for HIV + diffuse large B-cell lymphoma (DLBCL) fail to accurately predict patient outcomes. To develop a novel prognostic algorithm incorporating molecular tumor characteristics and HIV disease factors, we included 80 patients with HIV-related DLBCL diagnosed between 1996 and 2007. Immunohis...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1334121

    authors: Chao C,Silverberg MJ,Chen LH,Xu L,Martínez-Maza O,Abrams DI,Zha HD,Haque R,Said J

    更新日期:2018-02-01 00:00:00

  • Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells.

    abstract::Murine monoclonal antibody (mAb) 7C11 binds to the same cell surface epitope as anti-APO-1 and anti-Fas and reacts specifically with cells transfected with a cDNA encoding the human Fas antigen. Furthermore, incubation with 7C11 causes death of hematopoietic cell lines that express APO-1/Fas but not APO-1/Fas-negative...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199509051703

    authors: Robertson MJ,Manley TJ,Pichert G,Cameron C,Cochran KJ,Levine H,Ritz J

    更新日期:1995-03-01 00:00:00

  • Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone.

    abstract::The addition of rituximab (R) to standard CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy has altered the significance of previously recognized prognostic factors. We sought to re-examine the prognostic utility of (1) the number of extranodal sites of disease involvement, and (2) a prima...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.504872

    authors: Hui D,Proctor B,Donaldson J,Shenkier T,Hoskins P,Klasa R,Savage K,Chhanabhai M,Gascoyne RD,Connors JM,Sehn LH

    更新日期:2010-09-01 00:00:00

  • Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with acute myelogenous leukemia eligible for conventional allografting: a prospective study.

    abstract::Using a non-myeloablative stem cell trasplantation (NST) program, 25 allografts were prospectively given to 24 patients with acute myelogenous leukemia (AML) eligible for conventional allografting; 2 individuals had secondary forms of AML. The median age of the patients was 35 years, with a range of 12 to 56. All pati...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190310001642846

    authors: Ruiz-Argüelles GJ,Gómez-Almaguer D,David-Gomez-Rangel J,Vela-Ojeda J,Cantú-Rodríguez OG,Jaime-Pérez JC,González-Llano O,Herrera-Garza JL

    更新日期:2004-06-01 00:00:00

  • The role of bone marrow biopsy examination at diagnosis of chronic lymphocytic leukemia: a reappraisal.

    abstract::According to the International Workshop on Chronic Lymphocytic Leukemia/National Institutes of Health (iwCLL/NIH) guidelines for the diagnosis and treatment of chronic lymphocytic leukemia (CLL), bone marrow biopsy (BMB) is not required at diagnosis, however recommended before initiating treatment. That notwithstandin...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2013.780653

    authors: Baliakas P,Kanellis G,Stavroyianni N,Fameli M,Anagnostopoulos A,Stamatopoulos K,Papadaki T

    更新日期:2013-11-01 00:00:00

  • The international staging system for multiple myeloma is applicable in symptomatic Waldenstrom's macroglobulinemia.

    abstract::Several studies have indicated that age, hemoglobin and serum albumin are among the most important prognostic factors for survival of patients with Waldenstrom's macroglobulinemia (WM). Furthermore, recent data indicate that serum b2-microglobulin may be also significant. The recently proposed International Staging Sy...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190410001687512

    authors: Dimopoulos M,Gika D,Zervas K,Kyrtsonis M,Symeonidis A,Anagnostopoulos A,Bourantas K,Matsouka C,Pangalis G

    更新日期:2004-09-01 00:00:00

  • Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab.

    abstract::Hematologic malignancies are predominantly treated with chemotherapy or a combination of chemotherapy with monoclonal antibodies. Current treatment regimens often are not satisfactory due to severe side effects and a substantial proportion of relapsed patients. This has prompted the development of better tolerated and...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190902943077

    authors: Nagorsen D,Bargou R,Ruttinger D,Kufer P,Baeuerle PA,Zugmaier G

    更新日期:2009-06-01 00:00:00

  • Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis.

    abstract::In classical reduced-intensity conditioning (RIC) regimens, including the fludarabine and busulphan (BF) combination, sirolimus and tacrolimus (SIR-TAC) as graft vs host disease (GVHD) prophylaxis has shown acceptable results. The outcomes of SIR-TAC in a more intense RIC regimen as Thiotepa-fludarabine-busulfan (TBF)...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1788015

    authors: Fox ML,García-Cadenas I,Pérez AM,Villacampa G,Piñana JL,Ortí G,Montoro J,Roldán E,Bosch Vilaseca A,Martino R,Salamero O,Saavedra S,Hernandez-Boluda JC,Esquirol A,Sierra J,Sanz J,Solano C,Bosch F,Barba P,Valcarcel D

    更新日期:2020-08-01 00:00:00

  • STAT3, tumor microenvironment, and microvessel density in diffuse large B cell lymphomas.

    abstract::Constitutively activated STAT3 is correlated with more advanced clinical stage and overall poor survival of diffuse large B-cell lymphoma (DLBCL). The aim of this study was to evaluate STAT3 and Ki67 tumor cell expression, inflammatory cell infiltration, microvascular density in DLBCL bioptic specimens. RNA-scope show...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1678154

    authors: Tamma R,Ingravallo G,Gaudio F,Annese T,Albano F,Ruggieri S,Dicataldo M,Maiorano E,Specchia G,Ribatti D

    更新日期:2020-03-01 00:00:00

  • Cranial irradiation in adults diagnosed with acute myelogenous leukemia presenting with hyperleukocytosis and neurologic dysfunction.

    abstract::This study describes our institution's experience using whole brain radiation therapy (WBRT) to treat patients with acute myelogenous leukemia (AML) presenting with hyperleukocytosis. After approval by the institutional review board, we identified patients with AML and hyperleukocytosis using hospital records. The pri...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.797088

    authors: Ferro A,Jabbour SK,Taunk NK,Aisner J,Cohler A,Somalya S,Goyal S

    更新日期:2014-01-01 00:00:00

  • Hodgkin lymphoma in very young children: Clinical characteristics and outcome of treatment.

    abstract::In developed nations, Hodgkin lymphoma (HL) is rare in <5-year olds and represent a minority in developing countries. Little is reported about the biology and behavior of these very young patients compared with older children. 18.75% of our pediatric HL patients (0 - 14 years) were <5 years at diagnosis. This group ha...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190801947492

    authors: Belgaumi A,Al-Kofide A,Joseph N,Jamil-Malik R,Khafaga Y,Sabbah R

    更新日期:2008-05-01 00:00:00

  • Involvement of miR17 pathway in glucocorticoid-induced cell death in pediatric acute lymphoblastic leukemia.

    abstract::Analysis of the microRNA transcriptome following dexa- methasone treatment of the acute lymphocytic leukemia (ALL) cell line RS4;11 showed a global down-regulation of microRNA levels. MIR17HG was rapidly down-regulated following treatment, with chromatin immunoprecipitation (ChIP) analysis demonstrating the promoter t...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.678004

    authors: Harada M,Pokrovskaja-Tamm K,Söderhäll S,Heyman M,Grander D,Corcoran M

    更新日期:2012-10-01 00:00:00

  • Expression of HOX genes in acute leukemia cell lines with and without MLL translocations.

    abstract::In primary cells from acute leukemia patients, expression of the genes MEIS1, HOXA5, HOXA7 and HOXA9 has been reported to be correlated with the occurrence of MLL translocations. It was our aim to find out whether MLL mutant (MLLmu) and MLL wild-type (MLLwt) acute leukemia-derived cell lines might likewise be discrimi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190310001609942

    authors: Quentmeier H,Dirks WG,Macleod RA,Reinhardt J,Zaborski M,Drexler HG

    更新日期:2004-03-01 00:00:00

  • Identification and validation of a prognostic 8-gene signature for acute myeloid leukemia.

    abstract::In the present study, we aimed to identify some genes closely related to AML prognosis and investigate their potential roles. RNA-seq data of AML samples were accessed from the TCGA database and then analyzed in the Wilcox test. AML survival-related genes were selected and an 8-gene signature-based risk score model wa...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1742898

    authors: Zhang Y,Xiao L

    更新日期:2020-08-01 00:00:00

  • Expression of TEL-AML1 fusion transcripts and response to induction therapy in standard risk acute lymphoblastic leukemia.

    abstract::We prospectively examined the frequency of the t(12;21)TEL-AML1 fusion in 504 children with newly diagnosed standard risk ALL using RT-PCR assays. Cells from 95 patients (18.8%) were TEL-AML1+. There was a significantly higher frequency of pseudodiploidy among the TEL-AML1+ cases (39.4% versus 14.1%, P = 0.001), prima...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109097675

    authors: Uckun FM,Pallisgaard N,Hokland P,Navara C,Narla R,Gaynon PS,Sather H,Heerema N

    更新日期:2001-06-01 00:00:00

  • Angiogenic and lymphangiogenic molecules in hematological malignancies.

    abstract::In this review, the role of angiogenic and lymphangiogenic growth factors in hematological malignancies is summarized, alongside with possible therapeutic applications. Recent data demonstrate the importance of angiogenesis in hematologic malignancies including leukemia, lymphoma, and multiple myeloma. Expression of a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190290005964

    authors: Orpana A,Salven P

    更新日期:2002-02-01 00:00:00

  • Mechanisms of inhibition of IL-6-mediated immunoglobulin secretion by dexamethasone and suramin in human lymphoid and myeloma cell lines.

    abstract::The cytokine IL-6 has been proposed as an autocrine growth factor in multiple myeloma, and is also required for stimulation of immunoglobulin production and secretion in normal plasma cells and myeloma cells. In this study, we showed that secreted IL-6 is detectable by Western blot analysis in a panel of lymphoid and ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199209067610

    authors: Shiao RT,McLeskey SB,Khera SY,Wolfson A,Freter CE

    更新日期:1996-04-01 00:00:00

  • Cytokine receptor gene expression in peripheral blood mononuclear cells during graft-versus-host disease after allogeneic bone marrow transplantation.

    abstract::Interleukin-1 receptor type 1 (IL-1R), IL-2 receptor alpha subunit (IL-2R) and IL-6 receptor alpha subunit (IL-6R) mRNA expression in peripheral blood mononuclear cells (PBMC) in 17 patients who underwent allogeneic bone marrow transplantation (allo BMT) and 2 patients who underwent autologous transplantation were ana...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199509107899

    authors: Tanaka J,Imamura M,Kasai M,Zhu X,Kobayashi S,Hashino S,Higa T,Sakurada K,Asaka M

    更新日期:1995-10-01 00:00:00

  • Spontaneous regression of chemotherapy-refractory non-Hodgkin's lymphoma preceding the development of secondary leukaemia.

    abstract::In this report a rare case of spontaneous regression of a long-standing chemotherapy resistant low grade non-Hodgkin's lymphoma (NHL) of follicular small cleaved cell type is described. Extensive bulky lymphadenopathy substantially resolved, 7 months before the diagnosis of acute myelomonocytic leukaemia was establish...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199609051631

    authors: Grigg AP,Gascoyne RD,Barnett MJ

    更新日期:1996-01-01 00:00:00

  • Hematological remission and long term hematological control of acute myeloblastic leukemia induced and maintained by granulocyte-colony stimulating factor (G-CSF) therapy.

    abstract::We describe a case of a patient with CD34+, TdT+, CD13-, CD33-, MPO- undifferentiated acute leukemia who refused chemotherapy and who achieved complete hematological remission 14 months after the diagnosis, during a short course of granulocyte-colony stimulating factor (G-CSF) for neutropenia and life threatening infe...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819031000111053

    authors: Xavier L,Cunha M,Gonçalves C,Teixeira Mdos A,Coutinho J,Ribeiro AC,Lima M

    更新日期:2003-12-01 00:00:00

  • Why do B cell lymphoma fail to elicit clinically sufficient T cell immune responses?

    abstract::There is no doubt that human B cell lymphoma does not elicit a clinically sufficient T cell mediated immune response that results in tumor rejection. However, the mechanisms leading to this lack of T cell recognition and effector function are still not fully understood. Many potential mechanisms such as "ignorance" in...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199909167383

    authors: Schultze JL

    更新日期:1999-01-01 00:00:00

  • Influence of low dose rIL-2 treatment on endogenous cytokine production, expression of surface IL-2R and the level of soluble IL-2R in patients with minimal residual disease.

    abstract::This study was designed to investigate the immunomodulatory effect of low-dose IL-2 therapy (100 microg/day for 3 weeks) on interferon (IFN), tumor necrosis factor (TNF) production in vivo and in vitro and on the expression of IL-2Ralpha/beta and soluble form of IL-2Ralpha. Patients enrolled in the study suffered from...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199909145740

    authors: Dmoszyńska A,Kandefer-Szerszeń M,Roliński J,Legieć W,Kamińska T

    更新日期:1999-10-01 00:00:00

  • Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts.

    abstract::The efficacy of All-Trans Retinoic Acid (Atra) and Arsenic Trioxide (As(2)O(3)) in the treatment of Acute Promyelocytic Leukemia (APL) is well known. Further, these drugs inhibit cell growth and induce apoptosis in several cell lines, but few data are reported on leukemic blasts. The aim of this study was to evaluate ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190400014991

    authors: Cosenza M,Civallero M,Sacchi S,Marcheselli R,Pozzi S

    更新日期:2005-02-01 00:00:00

  • Chromosomal instability and ATR amplification gene in patients with persistent and polyclonal B-cell lymphocytosis (PPBL).

    abstract::Forty-three patients with persistent and polyclonal B-cell lymphocytosis (PPBL) were studied. The PPBL diagnosis was based on the presence of a polyclonal lymphocytosis and the detection of binucleated lymphoid cells on peripheral blood examination. In order to define the cytogenetic profile in these patients, convent...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194042000191738

    authors: Mossafa H,Tapia S,Flandrin G,Troussard X,Groupe Français d'Hématologie Cellulaire (GFHC).

    更新日期:2004-07-01 00:00:00

  • Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia.

    abstract::Rituximab (IDEC C2B8) is a chimeric human-mouse monoclonal anti-CD20 antibody that has been proven to be effective for the treatment of patients with CD20 positive leukemia and lymphoma. The level of CD20-expression in patients with B-cell chronic lymphocytic leukemia (B-CLL) is low in comparison to other B-cell lymph...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190210178

    authors: Perz J,Topaly J,Fruehauf S,Hensel M,Ho AD

    更新日期:2002-01-01 00:00:00